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Objective: Degenerative aortic valve disease is characterized by some of the histological features of
atherosclerotic lesions. Gamma-glutamyltransferase (GGT) has been recently implicated in pathogen-
esis of atherosclerosis, as well as in modulation of cells involved in calcium metabolism. We aimed to
evaluate the possible implication of this enzyme activity in aortic valve disease.
Methods: GGT immunohistochemistry was performed on valve leaﬂets of 64 patients with aortic valve
stenosis undergoing valve replacement. Fractional GGT activity in plasma and tissue was analysed in a
subgroup of cases by molecular exclusion chromatography.
Results: A close association was found between tissue extracellular GGT staining and lipid deposits
(p<0.0001). GGT was expressed by CD68-positive cells around neovessels, as well as by MMP-9- and
TRAP-positive multinucleated cells in the vicinity of bone metaplasia areas. Total plasma GGT levels
were associated with low HDL-c (p=0.028) and high triglycerides (p=0.017). Total GGT activity in tissue
was negatively correlated with the extent of valves calciﬁcation (p=0.03). Both serum and tissue GGT
levelswere negatively associatedwith severity of valve stenosis, as judged bypeak transvalvular pressure
gradients (p<0.0003 and p<0.002, respectively).
Conclusions: Accumulation of GGT activity inside the lipid component of valves leaﬂets suggests a com-
monmechanism of lesion shaping underlying both atherosclerosis and degenerative aortic valve disease.
Moreover, the ﬁnding of GGT expression in cells with an osteoclast-like phenotype, and its negative cor-
relation with both valves calciﬁcation and degree of valvular stenosis lend additional support to the
recently envisaged involvement of GGT in the homeostasis of calciﬁed tissues.
© 2010 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Calciﬁed aortic valve stenosis (AS), a common valve disease
in elderly, is the ﬁrst cause for surgical valve replacement in
United States and Europe [1]. AS is not a passive degenerative
disease, but an active cellular process which shares clinical and
histological similarities with atherosclerosis, including activated
inﬂammatory cells, lipid deposits, calciﬁed nodules and bone
tissue [2–5]. Moreover, it is associated with diabetes, hyperc-
holesterolemia, hypertension, smoking, male sex, elevated LDL-c
levels, and metabolic syndrome [6,7]. AS is characterized by patho-
logical remodeling and calciﬁcation processes, leading to varying
∗ Corresponding author. Tel.: +39 0577 233240; fax: +39 0577 48268.
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degrees of morphologic changes of the aortic valve leaﬂets, includ-
ing areas of increased thickening, distortion, rigidity, ﬁbrosis,
and the presence of bone-enchondral metaplasia [8]. Inﬂamma-
tion causes activation of myoﬁbroblasts, release of cytokines and
increased expression of matrix metalloproteinases (MMPs) and
their inhibitors (TIMPs) [2,9]. Activated myoﬁbroblasts seems to
express a variety of deﬁned phenotypes associated with remodel-
ing and repair [10]. In vitro studies showed that a subpopulation
of myoﬁbroblasts express chondrogenic and osteogenic markers
and form calciﬁc nodules in a pro-oxidant medium, while calcium
resorption was activated by cells with an osteoclastic phenotype
[11].
Recent studies have related gamma-glutamyltransferase (GGT),
an enzyme implicated in glutathione metabolism, with the patho-
genesis andprogressionof cardiovascular diseaseof atherosclerotic
nature. Evidence from epidemiological studies suggests that
0021-9150/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
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plasma GGT is associated with cardiovascular disease risk fac-
tors, including diabetes, hypertension, dyslipidemia, and with the
metabolic syndrome [12]. GGT is accumulated in atherosclerotic
lesions, likely as the result of insudation into the vesselwall of com-
plexes of the enzyme with circulating lipoproteins [13,14], and it
has been proposed that GGT may participate in disease progres-
sion by modulating one or more of the redox-sensitive processes
involved in atherosclerosis [15]. Other ﬁndings indicate that GGT
may act as a bone resorption factor, stimulating osteoclast forma-
tion in vitro and promoting osteoporosis in transgenicmice [16,17].
Recent studies have described the occurrence in plasma of four
GGT fractions with different molecular weights, whose differential
analysis can improve the signiﬁcance of GGT activity [18,19].
Against this background, we have performed a combined his-
tologic, histochemical and biochemical study of tissue and plasma
GGT in a group of patients undergoing aortic valve replacement, in
order to evaluate the possible implication of this enzyme activity
in aortic valve disease.
2. Materials
2.1. Patients and valve specimens collection
64 consecutive patients undergoing surgical aortic valve
replacement for severe and symptomatic calciﬁc AS were enrolled
in the study. Exclusion criteria were: any evidence of other
coexistent valvulardisease, post-rheumatic endocarditis, heart fail-
ure, chronic inﬂammatory or immunologic disease, cancer and
osteoporosis. Before surgery, all patients underwent a complete
echocardiographic study in order to assess regional and global
left ventricular function. To evaluate the degree of stenosis, peak
instantaneous transvalvularpressuregradientsweredetermined in
all patients. Two-dimensional complete echocardiographic studies
were independently performed by two trained echocardiogra-
phers, using the Vivid 7 SystemGE with a 4-MHz transducer.
During valve surgery, one of the excised leaﬂets was immedi-
ately frozen in liquid nitrogen for GGT activity determination, the
others were ﬁxed in buffered formalin for histological analysis. The
research protocol was approved by the local Ethics Committee and
performed in accordance with the ethical standards laid down in
the 1964 Declaration of Helsinki.
3. Methods
3.1. Main risk factors and clinical parameters
The cardiovascular risk factors considered in the study were:
age, gender, concomitant coronary artery disease, dyslipidemia,
diabetes mellitus and hypertension. The following clinical data
were evaluated in plasma taken from all patients before surgery:
total cholesterol, low-density lipoprotein cholesterol (LDL-c), high-
density lipoprotein cholesterol (HDL-c), triglycerides, ﬁbrinogen,
brain natriuretic peptide (BNP) and GGT.
3.2. Histology
All samples were ﬁxed in 10% buffered formalin for 24h
and decalciﬁed overnight with formic acid. Valve samples used
for histological analysis were taken vertically through the valve
cusp near the center of the each leaﬂets. Sections 5-m-thick
were obtained from parafﬁn-embedded samples and stained with
Hematoxylin–Eosin. Tissue neoangiogenesis and inﬂammation
were valued semiquantitatively according to a scoring system [20].
The presence of lipid deposits or atheroma was also evaluated
using semiquantitative analysis (0: absence; 1: small deposits; 2:
medium deposits with cholesterol needles; 3: large atheroma-like
structure). Tissue calciﬁcation was estimated on the basis of an
histological morphometric method (direct planimetry by counting
point) and expressed as the percentage of calciﬁed tissue respect to
the total area of the observed section (mean of 10 sections exam-
ined for each case). Bone-enchondral metaplasia was indicated as
presence/absence.
3.3. Immunohistochemistry
Immunohistochemical analysis was performed on all sam-
ples to detect cells and inﬂammatory markers: B-lymphocytes
(CD20, dilution 1:200; DAKO, Glostrup, Denmark), T-lymphocytes
(CD3, dilution 1:1000; Neomarkers, LabVision, Suffolk, UK), mono-
cytes/macrophages (CD68, dilution 1:1000; DAKO), ﬁbroblasts
(Vimentin, dilution 1:200; DAKO), smooth muscle cells (smooth
-actin, dilution 1:300; Neomarkers), osteoclasts (TRAP, dilution
1:50; Novocastra Laboratories, UK), GGT (polyclonal prepared in
our laboratory [13], dilution 1:900), MMP-2 (dilution 1:50; Chemi-
con International, Germany), MMP-9 (dilution 1:150; Chemicon
International). For detection, the IHC Select Immunoperoxi-
dase Secondary System (Chemicon International, Temecula, CA)
was used with a standard peroxidase enzyme substrate (3′,3′-
diamonobenzidine, DAB), yielding a dark-brown reaction product.
Sections were counterstained with hematoxylin. The expression
of GGT, MMP-2 and MMP-9 was graded on a semiquantita-
tive scale, ranging from 0 (no expression) to 3 (most intense
expression).
3.4. Fractional GGT activity in plasma and tissue
Fractional GGT was determined in plasma as compared to dis-
eased valve tissue. The amount of tissue available was sufﬁcient
to perform biochemical characterization of GGT protein in 12/27
cases. Analysis on plasma-EDTA samples was performed as pre-
viously described [19], using a FPLC system (AKTA puriﬁer, GE
Healthcare) equipped with a gel-ﬁltration column (Superose 6 HR
10/300 GL, GE Healthcare) and a ﬂuorescence detector (Jasco FP-
2020). Fractional GGT areawas calculatedwith the aid of a software
(MATLAB Version 7 MathWorks, Inc.) to resolve overlapping peaks.
Fraction termed “b-GGT” eluted between 10.0 and 12.0mL, “m-
GGT”between13.3and16.2mL, “s-GGT”between17.5and20.8mL,
“f-GGT” between 20.8 and 24.0mL.
For analysis of tissue GGT, frozen valve specimens from the
same patients (0.12±0.04g, range 0.08–0.28g) were pulverized
under liquid nitrogen and homogenized in cold hypotonic lysis
buffer (5mM sodium phosphate buffer pH 7.5, 0.015M NaCl).
Aliquots of crude homogenates were centrifuged at 10,000× g for
20min at 4 ◦C and the supernatants were ﬁltered with a 0.45m
PVDF ﬁlter (Millipore). Total GGT activity on crude homogenates
and the corresponding soluble fractions were determined using
gamma-glutamyl-p-nitroanilide as substrate and glycyl-glycine
as transpeptidation acceptor [21]. p-Nitroaniline formed in the
reaction was detected at 405nm (molar extinction coefﬁcient:
9200 L/(mol cm)). 1Unit of GGT activity was deﬁned as 1mol of
substrate transformed/mL/min. Fractional GGT analysis was con-
ducted on the soluble portion of valve homogenates.
3.5. Statistical analysis
Non-parametric Mann–Whitney and Spearman tests were
applied to analyse data that were not normally distributed, accord-
ing to the Kolgomorov–Smirnov test. Unpaired Student’s t test
was used for other comparisons. The signiﬁcance level was set at
p<0.05.
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Table 1
Clinical and echocardiographic features of the population studied (n=64).
Age, years 73.0±8.5
Gender, M/F 25/23
Hypertension, n (% of total) 45 (70.0)
Diabetes, n (% of total) 22 (34.3)
Coronary artery disease, n (% of total) 34 (53.0)
Total cholesterol, mg/dL 198.0±51.0
LDL cholesterol, mg/dL 125.0±40.0
HDL cholesterol, mg/dL 50.5±18.0
Triglycerides, mg/dL 107.7±85.1
GGT, U/L 30.9±46.6
CRP, mg/dL 0.7±1.0
Fibrinogen, mg/dL 305.0±84.0
BNP, pg/mL 314.1±301.0
Left ventricular ejection fraction 57.5±11.2
Max peak transvalvular pressure gradient, mmHg 83.9±29.3
Left ventricular chamber diameter, mm 51.0±8.0
Left ventricular mass index, g/m2 156.0±39.0
Data are mean± SD. BNP: brain natriuretic peptide; CRP: C-reactive protein;
GGT: gamma-glutamyltransferase;HDL:high-density lipoprotein; LDL: low-density
lipoprotein.
4. Experimental results
4.1. Clinical and echocardiographic ﬁndings
The main risk factors, clinical and echocardiographic features of
the studied population were summarized in Table 1. Our patients
were on average 73 years old and well distributed for gender.
They showed hypertension (70.3%), concomitant artery disease
(53.0%) and diabetes (34.3%) without signiﬁcant alterations of
serum cholesterol levels. All patients had left ventricular hyper-
trophy (i.e. LV mass index >135g/m2 in man, >110g/m2 in women)
with increased BNP plasma levels (measured as an index of heart
failure). None had left ventricular dilation. Mean ejection fraction
was 57.5±11.2.
4.2. Macroscopic ﬁndings
All aortic valves examined were tricuspid. Macroscopically,
stenotic valves were noticeably thickened, irregular, and showed
multiple, contiguous nodules extending from the base toward the
middle portion, with preserved commissures.
4.3. Histological ﬁndings
By histological analysis we observed that stenotic valves did
not preserve structural integrity of the three distinct layers and
showed the main features of atherosclerotic lesions: inﬂamma-
tion, neoangiogenesis, lipid deposits and calciﬁcations. The latter
were detectable in nodular form, with a “calcium replacement” of
valve ﬁbrous tissue. Calcium nodules were located on the aortic
side of the leaﬂet, and were surrounded by thin- and thick-walled
neovessels and inﬂammatory inﬁltrates. The latter were charac-
terized by macrophages, B- and T-lymphocytes and plasma cells,
and were strongly associated with areas of calciﬁcation and neoan-
giogenesis (p<0.0001). Cartilage tissue with chondrocytes and/or
ossiﬁcation areaswithbonemarrowwasobserved in28% (18/64) of
stenotic valves. Cholesterolneedles, lipid aggregates and foamcells,
sometimes arranged in atheroma-like structures, were also found
in 69% (44/64) of cases (Fig. 1a). Frequently, lipid deposits appeared
as comprised within calciﬁed nodules. Valve lipid deposits were
closely associated with decreased serum HDL-c levels (p=0.008),
while percentage of tissue calciﬁcation (54.82±31.8, mean± SD)
positively correlated with serum BNP (p=0.008) and with bone-
enchondral metaplasia (p=0.009).
4.4. Immunohistochemistry
All the remodeling markers studied (MMP-9, MMP-2 and GGT)
were expressed in valve leaﬂets. GGT staining was closely associ-
ated with lipid deposits (p<0.0001) and foam cells, localized both
in ﬁbrous tissue (Fig. 1b and c) and inside calciﬁed nodules. Dia-
Fig. 1. GGT expression in stenotic aortic valve (I): relationships of GGT with lipids and inﬂammatory cells. Panel a: cholesterol needles (Co) and foam cells (fc) are arranged in
atheroma-like structure. Panels b and c: lipids and foam cells (CD68+) are positive for GGT. Panel d: a large inﬂammatory inﬁltrate is located around thin-walled neovessels
near a calciﬁed nodule (*). Panels e and f: CD68+ cells within an inﬂammatory inﬁltrate express GGT. Hematoxylin–eosin, Immunohistochemistry with DAB revelation,
original magniﬁcation: 100× (a–d), 200× (e and f).
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Fig. 2. GGT expression in stenotic aortic valve (II): relationships of GGT with areas of calciﬁcation. Panels a and b: multinuclated giant cells (arrowheads), attached on the
surface of calciﬁed nodules (*), co-express GGT and MMP-9. Panels c and d: the same GGT-positive cells (arrowheads), observed near bone metaplasia areas (Bm), show an
osteoclast phenotype (TRAP+). Immunohistochemistry with DAB revelation, original magniﬁcation: 200×.
betes is a major factor in dyslipidemia; however, when analysed
in diabetic vs. non-diabetic patients neither serum GGT nor tis-
sue GGT levels were signiﬁcantly different (p=0.67 and p=0.15,
respectively). Tissue GGTwas expressed by CD68-positive cells (i.e.
monocytes/macrophages) around neovessels, and correlated with
neoangiogenesis (p=0.005) (Fig. 1d–f).
A higher magniﬁcation analysis of calciﬁed areas revealed
the presence of multinucleated giant cells, stained positively for
GGT. The same cells also expressed both MMP-9 and Tartrate-
ResistantAcid Phosphatase (TRAP), a speciﬁcmarker for osteoclasts
(Fig. 2). Score values of tissue GGT positively correlated with the
ones of MMP-9 (p=0.001). MMP-2 was expressed by myoﬁbrob-
lasts in the proximity of mineralization front of calciﬁed nodules
(data not shown).
4.5. GGT evaluation in plasma and tissue
Total plasma GGT was not increased, respect to normal values
(e.g., men ≤50U/L, women ≤40U/L) (Table 1), but higher levels
were associated with low HDL-c (p=0.028) and high triglycerides
levels (p=0.017) (Fig. 3a and b).
GGT activity of crude valve homogenates was found to range
between 9.2 and 199.9mU/g tissue (mean± SD: 61.9±46.2mU/g
tissue, n=27). A variable amount of valve GGTwas recovered in the
soluble portion of the homogenate [22.8±25.1mU/g tissue (31.5%
of total), n=27]. Importantly, higher degrees of valvular stenosis,
as judged by peak instantaneous transvalvular pressure gradients,
were signiﬁcantly associated with lower GGT levels both in serum
(p<0.0003) and in valve tissue extracts (p<0.002) (Fig. 3c).
Chromatographic fraction analysis of GGT showed that the low
molecular weight form (f-GGT) was the most abundant in serum;
on thecontrary,GGTrecovered fromvalve leaﬂetswasmostly in the
form of high molecular weight complexes (b-GGT), ls (Fig. 4). The
percentage distribution of GGT forms was signiﬁcantly different
also in the case of s-GGT, higher in plasma. Medium-high molec-
ular weight GGT form (m-GGT) – of which only traces are usually
present in plasma of patients within the normal range of total GGT
[19] – was undetectable in the valve specimens studied (Fig. 4).
Total GGT activity in tissue negatively correlated with the extent of
valve calciﬁcation (n=27, p=0.03).
5. Discussion
Previous studies have provided the evidence that degenerative
aortic valve disease may have an initiating mechanism based on
oxidative stress, similar to what is found in atherosclerosis [22,23].
Indeed valve stenosis and atherosclerosis share common risk fac-
tors and pathophysiological features. Only half of patients studied
however had signiﬁcant coronary artery disease (53%), while most
had hypertension (70.3%). Calciﬁcation, the prevalent tissue fea-
ture in diseased valves, presented as an active cellular-mediated
process strictly associated with inﬂammation and neoangiogene-
sis. Bone-enchondral metaplasia with bone marrow was observed
in a relevant amount of specimens (28%), in agreement with pub-
lished studies [24]. Inﬂammatory inﬁltrationwasmainly composed
of B- and T-lymphocytes and macrophages. We also observed
cholesterol needles, lipid aggregates and foam cells arranged in
atheroma-like structures, as previously reported [25,26]. In our
Author's personal copy
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Fig. 3. Correlation of GGT activity levels with plasma lipids proﬁle and severity of aortic valve stenosis. Correlation of total serum GGT with (a) serum HDL-c (n=47; p=0.028)
and (b) serum triglycerides (n=39; p=0.017). (c) Negative correlations of GGT levels in serum (n=51; p<0.0003) and valve tissue (n=27; p<0.002) with peak instantaneous
transvalvular pressure gradients, determined during echocardiographic evaluation of the patients.
patients total plasmaGGTwasnot increasedwith respect to normal
values (30.9±46.6), but higher levelswere associatedwith anunfa-
vorable lipid proﬁle (low HDL-c and high triglycerides). In a recent
study, plasmaGGT, inpatientswithin thecategoryof “normal-high”
GGT levels (<35U/L inwomen, <55U/L inmen),was correlatedwith
mortality from all vascular causes, speciﬁcally for ischemic heart
disease, while GGT above the reference category was a sensitive
predictor of hepatobiliary-related death [27].
As previously documented in studies on atherosclerotic lesions
[13], the present study for the ﬁrst time documents the pres-
ence of active GGT enzyme in diseased valve leaﬂets. The enzyme
was associated with lipid deposits and cellular elements, often in
proximity of areas of calciﬁcation and of neoformed vessels. GGT-
positive cells included multinucleated elements also stained for
MMP-9, themainmetalloproteinase secretedby inﬂammatory cells
[28] and favoring cellular migration and invasion through degra-
dation of matrix components [29,30]. Multinucleated giant cells
were attached to calciﬁed nodules and, besides GGT, they also
expressed TRAP and CD68, allowing to classify them as osteoclast-
like elements. It is conceivable that such multinucleated cells
may originate from the differentiation of monocytes/macrophages
drawn through neovessels into the tissue, where they could partic-
ipate in the calciﬁcation process and bone metaplasia [31]. Plasma
membrane GGT activity plays a critical role in recycling extra-
cellular glutathione and in maintaining intracellular antioxidant
homeostasis [32]; therefore, it could preserve the viability and the
activity of osteoclast-like cells in a oxidized environment. These
observations, enforced by the negative correlation between tis-
sue GGT total activity and calciﬁcation, may identify GGT as a
resorbing factor in the calciﬁcation process of stenotic aortic valve.
The role of GGT in tissue calcium balance was previously studied
by Niida and co-workers who demonstrated that an overexpres-
sion of gamma-glutamyltransferase in transgenic mice accelerated
bone resorption and caused osteoporosis [17], probably stimulat-
ing the receptor activator of nuclear factor-kappaB ligand (RANKL)
[16]. On the other hand, during metabolism of glutathione by GGT
the reactive metabolite cysteinyl-glycine is released and its sub-
sequent interactions are responsible for the production of oxygen
radicals and generation of a pro-oxidant extracellular environ-
ment [33]. Oxidant production is thought to enhance progression
of aortic valve calciﬁcation [11]. Thus, the fact that GGT accumula-
tion was predominant around calcifying nodules could suggest the
participation of GGT-dependent pro-oxidant processes in valvular
calciﬁcation. In vitro studies showed that exogenous superoxide,
hydrogen peroxide, or other oxidants increase the number and
activity of calcifying vascular cells (CVCs) [34], referred to as a
speciﬁc subpopulation of cells deriving from (de)differentiation
of vascular smooth muscle cells [35], pericytes or mesenchymal
cells [36]. In addition, reactive oxygen species (ROS) were shown
to mediate the increase in bone morphogenetic protein-2 (BMP2)
expression and signaling, thus favoring osteogenesis [37]. On the
other hand, ROS derived from NAD(P)H oxidase can also mediate
calcium resorption by osteoclasts [38].
GGT activity can be expressed by cellular elements participat-
ing in the inﬂammatory process [39], and cellular inﬁltrates might
be thus the source of GGT accumulating in diseased valves. Nev-
ertheless, as previously suggested [14,18], a signiﬁcant portion of
enzyme found in diseased tissue may as well derive from the insu-
dation of GGT macromolecular forms circulating in serum. The
ﬁndings of molecular characterization indeed show that three out
of four GGT fractions present in serum are also found in valve tis-
sue, although in different proportions. In AS lesions high molecular
weight b-GGT form was in fact predominant, while in serum s-GGT
and f-GGT were more abundant. Such difference can be explained
by the fact that b-GGT is the form released by cells [40], and
therefore valve tissue b-GGT may be more abundant due to active
secretion by inﬁltrating macrophages. Actually, b-GGT recovered
from AS lesions presented with slightly higher molecular weight,
pointing to the possible formation in tissue of even larger protein
aggregates as compared to serum. Previous studies in atheroscle-
rotic plaques indicated the tendency of insudated GGT complexes
to become less negatively charged and to aggregate, possibly due
to protein desialylation effected by inﬂammatory cells [13].
Concerning the origins of circulating GGT in AS patients, it is
doubtful that the diseased valve tissue may contribute to release
into the blood signiﬁcant amounts of the enzyme. The association
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Fig. 4. GGT fraction analysis in serum and tissue of stenotic aortic valve patients.
The four GGT chromatographic fractions, termed b-GGT, m-GGT, s-GGT and f-GGT
[19], were determined after homogenization and size exclusion chromatography, in
valve tissue (continuous lines, right y-axis), and for comparison in sera of the cor-
responding patients (dotted lines, left y-axis). (a) Results for three representative
patients are shown (I, II and III). (b) Relative abundance of four GGT molecular iso-
forms in plasma and valve tissue. N.D. not detectable. Data shown are means± SD;
*p<0.02, **p<0.005, ***p<0.0001 (unpaired Student’s t test).
observed between higher serum GGT values and alterations of the
lipid proﬁle (low HDL-c and high triglycerides) might suggest the
concomitance of liver dysfunction, and that this may contribute to
serum GGT changes. None of the patients however presented with
excess alcohol consumption or alterations of other liver parame-
ters. A positive correlation was present between serum GGT and
ALT levels (p<0.016, n=64), however serum ALT and AST levels
were not associated with either LDL-c, HDL-c or triglycerides.
A limitation of the present study lies in the fact that the obser-
vations made in diseased aortic valve tissue could not be compared
with normal valves, for obvious reasons. Alternatives could be
offered by: specimens obtained during autopsies, in which how-
ever post-mortemalterationswouldmake any conclusionunsound
or by aortic valves with secondary insufﬁciency obtained from
explanted hearth with dilated ventricule; the latter cannot be con-
sidered as healthy tissues. The study was therefore focused on a
histological, histochemical and biochemical analysis, as detailed as
possible, of AS lesions only.
In conclusion, data reported in the present study suggest the
possible implication of GGT activity in the pathogenesis of stenotic
aortic valve disease, as previously envisaged for atherosclerosis.
Serum GGT levels, usually considered as a marker of alcohol con-
sumption and/or of oxidative stress, have been recently shown to
have important prognostic signiﬁcance in cardiovascular diseases,
identifying patients subsets at higher risk of events and requir-
ing speciﬁc and enhanced therapeutic efforts [41,42]. Our ﬁndings
show that higher plasma GGT levels, even if within normal range,
are associated with an unfavorable lipid proﬁle (Fig. 3a and b). GGT
accumulates in atherosclerotic plaques, where the redox processes
deriving from its activity, might participate at several levels in the
progressionof lesions [15]. Thepresent study, for theﬁrst time, doc-
uments the accumulation of GGT in lipid deposits of stenotic aortic
valves as well, where the same kind of processes can be therefore
hypothesized. In serum of healthy subjects, b-GGT is signiﬁcantly
correlated with serum levels of triglycerides [43]. The same was
apparent in the AS patients studied (Fig. 3b), in which b-GGT was
found to be the form predominantly accumulated in diseased valve
tissue.
Altogether, the present study indicates that GGT activity may
play a complex role in the pathogenesis of aortic valve stenosis. In
fact, the negative correlation of serum and tissue GGT levels with
severity of valve stenosis (peak transvalvular pressure gradients),
the negative association of tissueGGT levelswith valvular calciﬁca-
tion, as well as the localization of GGT expression in osteoclast-like
elements in the proximity of calciﬁed nodules, suggest that the
enzyme might play as a resorbing factor in calciﬁcation remodel-
ing, in apparent agreementwith the recently envisaged implication
of GGT in bone homeostasis [16,17]. Further studies are thus war-
ranted in order to elucidate (i) the connections linking plasma lipid
patterns to alterations of plasmatic GGT forms, (ii) the molecular
mechanism of GGT involvement in valve calciﬁcation remodeling,
and (iii) the signiﬁcance of these aspects for the prognosis of aortic
valve disease.
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